methyl 1-isocyanato-1-cyclohexanecarboxylate | 144876-59-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 1-isocyanato-1-cyclohexanecarboxylate
• 英文别名: methyl 1-isocyanatocyclohexanecarboxylate；methyl 1-isocyanatocyclohexane-1-carboxylate
• CAS: 144876-59-5
• 化学式: C₉H₁₃NO₃
• 分子量: 183.207
• InChiKey: FSNBFWXIYAAFOP-UHFFFAOYSA-N

物化性质

• 沸点：
  238.7±23.0 °C(Predicted)
• 密度：
  1.15±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  55.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 1-isocyanato-1-cyclohexanecarboxylate 在 palladium dihydroxide lithium hydroxide 、 二苯基磷酸 、 氢气 、 碳酸氢钠 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 25.0~100.0 ℃ 、310.27 kPa 条件下， 反应 129.0h， 生成 <10R-(10α,14α,17α)>-10-(1H-indol-3-ylmethyl)-10-methyl-8,11,16,19-tetraoxo-14-phenyl-7,9,12,15,18-pentaazaspiro<5,13>nonadecane-17-acetic acid
  参考文献：
  名称：

  Synthesis and CCK-B binding affinities of cyclic analogues of the potent and selective CCK-B receptor antagonist Cl-988

  摘要：

  A selected series of 14-membered macrocyclic compounds (2) has been prepared as potential CCK-B receptor selective ligands. The efficiency of a number of cyclising reagents has also been evaluated.

  DOI：

  10.1016/s0040-4020(01)86596-0
• 作为产物：
  描述：

  1-氨基-1-环己基甲酸 在 氯化亚砜 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 4.0h， 生成 methyl 1-isocyanato-1-cyclohexanecarboxylate
  参考文献：
  名称：

  Synthesis and CCK-B binding affinities of cyclic analogues of the potent and selective CCK-B receptor antagonist Cl-988

  摘要：

  A selected series of 14-membered macrocyclic compounds (2) has been prepared as potential CCK-B receptor selective ligands. The efficiency of a number of cyclising reagents has also been evaluated.

  DOI：

  10.1016/s0040-4020(01)86596-0

文献信息

• Design, synthesis, and evaluation of a novel series of macrocyclic inhibitors of norovirus 3CL protease
  作者：Vishnu C. Damalanka、Yunjeong Kim、Anushka C. Galasiti Kankanamalage、Gerald H. Lushington、Nurjahan Mehzabeen、Kevin P. Battaile、Scott Lovell、Kyeong-Ok Chang、William C. Groutas

  DOI：10.1016/j.ejmech.2016.12.033

  日期：2017.2

  novel class of macrocyclic inhibitors of norovirus 3C-like protease, a cysteine protease that is essential for virus replication. SAR, structural, and biochemical studies were carried out to ascertain the effect of structure on pharmacological activity and permeability. Insights gained from these studies have laid a solid foundation for capitalizing on the therapeutic potential of the series of inhibitors

  诺如病毒感染对全世界的公共卫生有重大影响，但目前尚缺乏诺如病毒特有的疗法和预防措施。这份报告描述了新型的诺如病毒3C样蛋白酶的大环抑制剂的发现，这是一种对病毒复制至关重要的半胱氨酸蛋白酶。进行了SAR，结构和生化研究，以确定结构对药理活性和通透性的影响。从这些研究中获得的见解为利用本文所述的一系列抑制剂的治疗潜力奠定了坚实的基础。
• GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS
  申请人：Ahmad Nadia Mamoona

  公开号：US20120004273A1

  公开（公告）日：2012-01-05

  Disclosed herein are compounds of formula (I) and: wherein: X is Ar—C(O)CH(R 20 )— or Ar 1 —NHC(O)CH 2 —; and Ar is: naphthyl optionally substituted with one or more groups Y; pyridyl optionally substituted with one or more groups Z; or the group Ar 1 etc, these compounds being useful for treating neurological diseases such as schizophrenia, dementia or attention deficit disorder.

  本文披露了公式（I）和以下化合物： 其中： X是Ar-C（O）CH（R20）-或Ar1-NHC（O）CH2-; 而Ar是： 萘基，可选择地用一个或多个基团Y取代; 吡啶基，可选择地用一个或多个基团Z取代; 或者Ar1等，这些化合物对治疗神经疾病如精神分裂症、痴呆症或注意力缺陷障碍有用。
• WO2008/92878
  申请人：——

  公开号：——

  公开（公告）日：——
• Toward the Back-Up of Boceprevir (SCH 503034): Discovery of New Extended P₄-Capped Ketoamide Inhibitors of Hepatitis C Virus NS3 Serine Protease with Improved Potency and Pharmacokinetic Profiles
  作者：Stéphane L. Bogen、Weidong Pan、Sumei Ruan、Latha G. Nair、Ashok Arasappan、Frank Bennett、Kevin X. Chen、Edwin Jao、Srikanth Venkatraman、Bancha Vibulbhan、Rong Liu、Kuo-Chi Cheng、Zhuyan Guo、Xiao Tong、Anil K. Saksena、Viyyoor Girijavallabhan、F. George Njoroge

  DOI：10.1021/jm801632a

  日期：2009.6.25

  Hepatitis C is the most prevalent liver disease. Viral hepatitis C (HCV), a small (+)-RNA virus, infects chronically an estimated 300 million people worldwide. Results of Phase I clinical studies with our first generation HCV inhibitor Boceprevir, SCH 503034 (1), presented at the 56th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) were encouraging, and thus, additional human clinical studies are underway. In view of the positive data from our first generation compound, further work aimed at optimizing its overall profile was undertaken. Herein, we report that extension of our earlier inhibitor to the P-4 pocket and optimization of the P-1' capping led to the discovery of new ketoamide inhibitors of the HCV NS3 serine protease with improved in vitro potency. In addition to being potent inhibitors of HCV subgenomic RNA replication, some of the new P-4-capped inhibitors were also found to have improved PK profile.
• NOVEL AMINOCYCLOHEXANE DERIVATIVES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1311475A1

  公开（公告）日：2003-05-21